Regorafenib (BAY 73-4506 commercial name Stivarga) is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. It is currently being studied as a potential treatment option in multiple tumor types.
This page contains content from the copyrighted Wikipedia article "Regorafenib"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
